NCT05171348View on ClinicalTrials.gov

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

October 11, 2022

Study Completion Date

October 11, 2022

Conditions
Asthma
Interventions
DRUG

CM326

a humanized monoclonal antibody

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05171348 - A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter